¼¼°èÀÇ ¾ËºÎÅ×·Ñ(Albuterol) ½ÃÀå º¸°í¼­(2025³â)
Albuterol Global Market Report 2025
»óǰÄÚµå : 1760452
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 175 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,222,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 8,993,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,765,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¾ËºÎÅ×·Ñ ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¼ö ³â°£ °­·ÂÇÑ ¼ºÀåÀÌ Àü¸ÁµÉ ¿¹Á¤ÀÔ´Ï´Ù. ¿¹Ãø ±â°£ÀÇ ¼ºÀåÀº °¡Á¤¿ë ÇコÄÉ¾î ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, È£Èí±â ¾à¹° ¿¬±¸¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡, °³ÀÎ ¸ÂÃãÇü ÀÇÇп¡ ´ëÇÑ °ü½É Áõ°¡, µðÁöÅÐ ÈíÀÔ±âÀÇ Ã¤Åà Áõ°¡, ¶óÀÌÇÁ½ºÅ¸ÀÏ °ü·Ã È£Èí±â ÁúȯÀÇ À¯º´·ü Áõ°¡¿¡ ±âÀÎÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸¸¼º È£Èí±â ÁúȯÀÇ À¯º´·ü Áõ°¡´Â ¾ËºÎÅ×·Ñ ½ÃÀåÀÇ È®´ë¸¦ ÃËÁøÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. È£Èí ¹®Á¦·Î À̾îÁý´Ï´Ù. È£Èí±â Áúȯ Áõ°¡´Â ÁÖ·Î ´ë±â ¿À¿°ÀÇ ½É°¢È­¿Í °ü·ÃÀÌ ÀÖÀ¸¸ç, À¯ÇØÇÑ ¿À¿° ¹°Áú¿¡ ´ëÇÑ ³ëÃâÀÌ Áõ°¡Çϸé±âµµ°¡ ¾ÇÈ­µÇ°í Æó ±â´ÉÀÌ ¼Õ»óµË´Ï´Ù. È£ÈíÀ» °¡¼ÓÈ­Çϰí È£ÈíÀ» ÆíÇÏ°Ô ÇÔÀ¸·Î½á ¸¸¼º È£Èí±â ÁúȯÀÇ Áõ»óÀ» ¿ÏÈ­ÇÕ´Ï´Ù. È£ÁÖ Åë°èûÀº COPDÀÇ À¯º´·üÀÌ 2021³â 2.4%¿¡¼­ 2022³â 2.5%·Î Áõ°¡Çß´Ù°í º¸°íÇß½À´Ï´Ù. ¸¸¼º È£Èí±â ÁúȯÀÇ ÀÌȯÀ² Áõ°¡°¡ ¾ËºÎÅ×·Ñ ½ÃÀå ¼ºÀå¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

¾ËºÎÅ×·Ñ ½ÃÀåÀÇ ÁÖ¿ä Âü°¡ ±â¾÷Àº ¸¸¼º È£Èí±â Áúȯ ȯÀÚ¿¡ ´ëÇÑ Á¢±ÙÀ» È®´ëÇϱâ À§ÇØ Ã·´Ü Á¦Ç°, ƯÈ÷ Á¦³×¸¯ ÈíÀÔÁ¦ÀÇ °³¹ß¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. Amphastar Pharmaceuticals Inc.´Â ¾ËºÎÅ×·Ñ Sulfate ÈíÀÔ ¿¡¾î·ÎÁ¹ÀÇ ¾à½Ä ½Å¾à ½ÂÀÎ ½Åû(ANDA)ÀÇ FDA ½ÂÀÎÀ» ÃëµæÇß½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå - ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ¹«¿ªÀüÀï°ú °ü¼¼, Äڷγª ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°/±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, Àü·«

Á¦36Àå ºÎ·Ï

SHW
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Albuterol is a fast-acting bronchodilator used to treat or prevent bronchospasm (airway narrowing). It works by relaxing the muscles around the airways, helping to open them up and make breathing easier. Albuterol takes effect within minutes, making it well-suited for rapid relief during episodes of respiratory distress.

The primary product types of albuterol include inhalers, nebulizers, tablets, and syrups. Inhalers are portable devices that deliver albuterol directly to the lungs, offering fast-acting relief and immediate results in respiratory emergencies. Albuterol can be administered via various routes such as inhalation, oral, and intravenous. It is distributed through multiple channels, including hospital pharmacies, retail pharmacies, online pharmacies, and others. The medication is used for several conditions including asthma, chronic obstructive pulmonary disease (COPD), bronchospasm, and more, and serves various end-users such as hospitals, clinics, home care environments, and pharmacies.

The albuterol market research report is one of a series of new reports from The Business Research Company that provides albuterol market statistics, including the albuterol industry global market size, regional shares, competitors with the albuterol market share, detailed albuterol market segments, market trends, and opportunities, and any further data you may need to thrive in the albuterol industry. This albuterol market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The albuterol market size has grown strongly in recent years. It will grow from $4.47 billion in 2024 to $4.79 billion in 2025 at a compound annual growth rate (CAGR) of 7.0%. The growth during the historic period can be attributed to increased awareness of respiratory health, rising air pollution levels, higher demand for quick-relief inhalers, greater adoption of nebulizers, and expanded availability of generic albuterol.

The albuterol market size is expected to see strong growth in the next few years. It will grow to $6.29 billion in 2029 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to the rising demand for home healthcare solutions, increased investment in respiratory drug research, a growing focus on personalized medicine, the rising adoption of digital inhalers, and the increasing prevalence of lifestyle-related respiratory disorders. Major trends during the forecast period include advancements in inhaler technology, innovations in patient monitoring systems, progress in AI-driven treatment plans, the integration of telemedicine with respiratory care, and developments in personalized asthma management.

The increasing prevalence of chronic respiratory conditions is anticipated to drive the expansion of the albuterol market. Chronic respiratory conditions are long-term illnesses affecting the lungs and airways, leading to persistent breathing issues such as asthma, chronic obstructive pulmonary disease (COPD), and bronchitis. The rise in respiratory ailments is primarily linked to escalating air pollution, which elevates exposure to harmful pollutants that aggravate the airways and impair lung function. Albuterol mitigates symptoms of chronic respiratory diseases by relaxing airway muscles, enhancing airflow, and easing breathing. It offers rapid relief from symptoms such as wheezing, coughing, and shortness of breath. For example, in December 2023, the Australian Bureau of Statistics, a government agency in Australia, reported that the prevalence of COPD increased from 2.4% in 2021 to 2.5% in 2022. Consequently, the growing incidence of chronic respiratory conditions is fueling the albuterol market growth.

Key players in the albuterol market are concentrating on the development of advanced products, particularly generic inhalation medications, to broaden access for individuals with chronic respiratory diseases. Generic inhalers are non-branded alternatives that deliver the same active ingredients, dosages, and therapeutic benefits as their branded versions, generally at a more affordable price. For instance, in May 2024, Amphastar Pharmaceuticals Inc., a pharmaceutical company based in the United States, received FDA approval for its abbreviated new drug application (ANDA) for Albuterol Sulfate inhalation aerosol. This product is intended for treating or preventing bronchospasm in patients aged four and older. The inhalation aerosol functions by relaxing muscles in the airways to enhance airflow, providing swift relief from symptoms such as wheezing and breathing difficulty in conditions such as asthma.

In March 2022, Sandoz Group AG, a pharmaceutical company headquartered in Switzerland, acquired Coalesce Product Development Limited for an undisclosed sum. The acquisition aims to bolster Sandoz's respiratory offerings in the US and European markets by leveraging Coalesce's expertise in drug delivery systems. This move is set to enhance Sandoz's pipeline of complex respiratory medications and improve access to high-quality treatments. Coalesce Product Development Limited is a UK-based firm specializing in the design and development of medical devices, including albuterol sulfate metered-dose inhalers.

Major players in the albuterol market are Merck And Co. Inc., AstraZeneca PLC, GlaxoSmithKline plc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Mylan N.V., Sandoz Group AG, Sun Pharmaceutical Industries Ltd., Perrigo Company plc, AptarGroup Inc., Chiesi Farmaceutici S.p.A., Cipla Limited, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals Inc., Lupin Limited, Zydus Lifesciences Limited, Nephron Pharmaceuticals Corporation, Glenmark Pharmaceuticals Limited, Amphastar Pharmaceuticals Inc., Arven Pharmaceuticals A.S., Hi-Tech Pharmaceuticals Inc., Jewim Pharmaceutical (Shandong) Co. Ltd.

North America was the largest region in the albuterol market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in albuterol report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the albuterol market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The albuterol market consists of sales of metered-dose inhalers, dry powder inhalers (DPIs), and solution forms of albuterol, including both branded and generic versions. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Albuterol Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on albuterol market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for albuterol ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The albuterol market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Albuterol Market Characteristics

3. Albuterol Market Trends And Strategies

4. Albuterol Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Albuterol Growth Analysis And Strategic Analysis Framework

6. Albuterol Market Segmentation

7. Albuterol Market Regional And Country Analysis

8. Asia-Pacific Albuterol Market

9. China Albuterol Market

10. India Albuterol Market

11. Japan Albuterol Market

12. Australia Albuterol Market

13. Indonesia Albuterol Market

14. South Korea Albuterol Market

15. Western Europe Albuterol Market

16. UK Albuterol Market

17. Germany Albuterol Market

18. France Albuterol Market

19. Italy Albuterol Market

20. Spain Albuterol Market

21. Eastern Europe Albuterol Market

22. Russia Albuterol Market

23. North America Albuterol Market

24. USA Albuterol Market

25. Canada Albuterol Market

26. South America Albuterol Market

27. Brazil Albuterol Market

28. Middle East Albuterol Market

29. Africa Albuterol Market

30. Albuterol Market Competitive Landscape And Company Profiles

31. Albuterol Market Other Major And Innovative Companies

32. Global Albuterol Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Albuterol Market

34. Recent Developments In The Albuterol Market

35. Albuterol Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â